Full Length Research Paper
References
Adrogue HJ, Madias NE (2014). Sodium surfeit and potassium deficit: keys to the pathogenesis of hypertension. J. Am. Soc. Hypertens. 8(3):203-213. |
|
Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG (2005) Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J. Am. Soc. Nephrol. 16:1920-1928. |
|
Cunhan AR, Umbelino B, Correia LM, Fritsch M (2012). Magnesium and vascular changes in Hypertension Int. J. Hypertens. 754250. |
|
Chobanian AV, Bakris GL, Black HR (2003). The 7th Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2003). U.S. Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program 2003 JAMA 289(19):2560-2571. |
|
da Silva A, doCarmi J, Dubinion J, Hall JE (2009). Role of sympathetic nervous system in obesity related hypertension. Curr. Hypertens. Rep. 11:206. |
|
Grassi G, Seravalle G, Quarti-Trevano F. The "neuroadrenergic hypothesis" in hypertension: current evidence (2010). Exp. Physiol. 95:581-6. |
|
Hu G, Xu X, Liang X, Yang X, Zhang J, Simayi Z, Chen Y (2013). Associations of plasma atrial natriuretic peptide and electrolyte levels with essential hypertension. Exp. Ther. Med. 5(5):1439-1443. |
|
Huang A, Sun D, Koller A (2000). Shear stress-induced release of prostaglandin H2 in the arterioles of hypertensive rats. Hypertension 35:925-30. |
|
Ikeda T, Gomi T, Sasaki Y (1994). Effects of swim training on blood pressure, catecholamines and prostaglandins in spontaneously hypertensive rats. Jpn. Heart J. 35:205-11. |
|
Kanbay M, Bayram Y, Solak Y, Sanders PW (2013). Dietary potassium: a key mediator of the cardiovascular response to dietary sodium chloride. J. Am. Soc. Hypertens. 7:395-400. |
|
Kotchen TA (2011). Hypertensive vascular disease Harrison's Principle of Internal Medicine, 18th edn. McGraw-Hill, New York. Drug Information Handbook: A Comprehensive Resource for Clinicians and Healthcare Professionals (2013.) 22nd edn. Lexi-Comp, Hudson, OH. |
|
Lim SS, Vos T, Flaxman AD (2012). A comparative risk assessment of burden of disease and injury attributed to 67 risk factors and risk factor clusters in 21 regions, 19902013: a systemic analysis for the Global Burden of Disease Study. Lancet 380:2224-60. |
|
Mironova E, Chen Y, Pao AC, Roos KP, Kohan DE, Bugaj V, Stockand JD (2015). Activation of ENaC by AVP contributes to the urinary concentrating mechanism and dilution of plasma. Am. J. Physiol. Renal Physiol. 308(3):F237-F243. |
|
Mulrow PJ (1999). Angiotensin II and aldosterone regulation Regul. Pept. 80:27-30. |
|
Okeahialam BN, Isamade EL, Ibrahim TM, Anjoorin FI (1998). The effect of lacidipine on patients with mild to moderate hypertension and the effect of a combination of lacidipine and hydrochlorothiazide in the treatment of hypertension uncontrolled after four weeks of lacidipine treatment: an open study. West Afr. J. Med. 17:42-46. |
|
Paczwa P, Budzikowski AS, Szczepanska-Sadowska E (1997). Enhancement of central pressor effect of AVP in SHR and WKY rats by intracranial N (G)-nitro-L-arginine. Brain Res. 748(1-2):51-61. |
|
Reid IA (1998). The renin-angiotensin system: physiology, pathophysiology, and pharmacology. Adv. Physiol. Educ. 20:S237-45. |
|
Salako BL, Kadiri S, Walker O, Fehintola FA (1998). Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: a double-blind comparison with hydrochlorothiazide. Afr. J. Med. Med. Sci. 27(1-2):73-75. |
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0